Infinion Biopharma Ltd IPO

Last Updated: 09 February 2022 10:08 AM by 5Paisa

Details on IPO

Infinion Biopharma has filed preliminary papers with Sebi to raise funds through an initial share sale. The initial public offering (IPO) comprises the sale of 45 lakh equity shares at a face value of Rs. 10 per share. The company may consider a pre-IPO placement of up to 7 lakh equity shares.
Aryaman Financial Services is the sole book-running lead manager to the issue.

Objective of the Issue
The net proceeds will be used towards 
1.    investment in Mobius Biomedical Inc, 
2.    acquisition of licenses for product development of skincare and women's health products 
3.    working capital requirements
 

Infinion Biopharma is an innovation driven life sciences company that combines biophysics and engineering with traditional pharmacology and biochemistry to produce high-value, innovative products across a range of therapeutic areas. It has created a global scientific ecosystem multiple disciplines including biophysics, biochemistry, pharmacology and biotechnology to create innovative products to manage and treat various diseases.
It is engaged in the business of pharmaceutical licensing and commercialization of high-value, innovative products across a range of therapeutic areas with focus areas including: 
•    Formulation Technology – to enable better products for skin care and women‘s health 
•    Biotechnology – to enable better diagnostic and treatment options for neurological conditions 
•    Process Technology – to enable better processes to manufacture biological drugs
The significant investment in Ansella Therapeutics Inc. has enabled it to acquire the product licenses and provide the ability to develop and market the products created using innovative formulations in India. Further, investment in Aurum Biosciences Ltd. allows access to the development of a new molecule for stroke management and other neurological conditions. Also, some of the funds from the proceeds will be used to invest in another research based company, Mobius Biomedical Inc., situated in Lowell, USA enabling to gain access to new process technologies for manufacturing high-value biopharmaceuticals including biologics and biosimilars.
The company’s ultimate vision is to bring new technology to India along with the rest of the world, and enable the Indian people to access high-end innovative treatments as and when the same are launched world-wide.

Financials